HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
m Updated Assigned to column |
updated assignment column |
||
| Line 1,673: | Line 1,673: | ||
|- | |- | ||
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi | ||
|4/15/25|| || | |4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Splenic Marginal Zone Lymphoma | |Splenic Marginal Zone Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,706: | Line 1,706: | ||
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
|Sent e-mail to prev authors nor reply | |||
| | | | ||
| | | | ||
| Line 1,722: | Line 1,722: | ||
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
|Sent e-mail to prev authors nor reply | |||
| | | | ||
| | | | ||
| Line 1,740: | Line 1,740: | ||
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]] | |[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]] | ||
|Disease | |Disease | ||
| | |Molly Walkenhorst | ||
| | | | ||
|9/4/2025 sent E-mail reminder | |||
| | | | ||
| | | | ||
| Line 1,772: | Line 1,772: | ||
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
| | |Andrew Ly | ||
| | | | ||
|9/4/2025 sent E-mail reminder | |||
| | | | ||
| | | | ||
| Line 1,806: | Line 1,806: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,822: | Line 1,822: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,838: | Line 1,838: | ||
| | | | ||
| | | | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
| | | | ||
| | | | ||
| Line 1,854: | Line 1,854: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/ | ||
|Pending | |Pending | ||
| | | | ||
| Line 2,342: | Line 2,342: | ||
!Prior Notes (4th Edition) | !Prior Notes (4th Edition) | ||
|- | |- | ||
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo | |[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo and Zhenya Tang | ||
|4/14/25||7/14/25 | |4/14/25||7/14/25 | ||
9/4/2025 Sent E-mail reminder to Dr. Tang | |||
|Pending|| ||SG | |||
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | | ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | ||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | ||